Industries > Pharma > Biologics Market Trends and Forecasts 2018-2028

Biologics Market Trends and Forecasts 2018-2028

Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies

PUBLISHED: 14 November 2018
PAGES: 303
PRODUCT CODE: PHA0341

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE

The global biologics market is estimated to reach $250bn in 2023. The market is expected to grow at a CAGR of 4.8% from 2018 to 2023. In 2017, the monoclonal antibodies submarket held 36.3% share of the global biologics market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 303-page report you will receive 166 charts– all unavailable elsewhere.

The 303-page report provides clear detailed insight into the global biologics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Biologics Market outlook from 2018-2028

Global Biologics Submarkets analysis and forecast from 2018-2028:
Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents
Monoclonal antibodies (mAbs)
Fusion proteins
Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy
Vaccines

• Analysis and forecast from 2018-2028 for selected leading biologics in the market:
• Lantus
• NovoLog/NovoRapid
• Humalog
• Avonex
• Rebif
• Humira
• Remicade
• Tysabri
• Herceptin
• Kadcyla
• Perjeta
• Enbrel
• Eylea
• OsteoCel Plus
• Trinity Evolution and Trinity Elite
• Apligraf
• Dermagraft
• IMLYGIC

Biologics Market Trends and Forecasts 2018-2028

• This report provides individual revenue forecasts from 2018-2028 for these national markets:
• The US
• Japan
• Germany
• France
• UK
• Italy
• Spain
• China
• India
• Russia
• Brazil

• Our study discusses the selected leading companies that are the major players in the biologics market:
• AbbVie
• Amgen
• AstraZeneca
• Bayer
• Eli Lilly
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis
• Pfizer
• Roche
• Sanofi S.A.

• This report discusses factors that drive and restrain this market. As well as opportunities and trends in this market.

• This report discusses the SWOT and STEP Analysis of the biologics market.

Visiongain’s study is intended for anyone requiring commercial analyses for the biologics market. You find data, trends and predictions.

Buy our report today Biologics Market Trends and Forecasts 2018-2028: Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Biologics Market Trends and Forecasts 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Biologics Market Trends and Forecasts 2018-2028


Latest Pharma news

“The worldwide industry for silicone additives is likely to experience important development”, says Visiongain

It is anticipated that the benefits of silicone additives such as elevated drop, marine strength, and leveling & humidity regulate will boost their use in cosmetics, coatings, and paint applications.

16 October 2019

READ

“Global nephrology and urology devices market is anticipated to surpass USD 39 Bn by 2030”, says Visiongain

Nephrology is a field of medicine that is concerned with studying kidney function, treating kidney issues, and therapy for renal substitute.

16 October 2019

READ

“The global Nasal Drug Delivery Technology market is anticipated to surpass USD 80 Billion by 2030”, says Visiongain

Asia Pacific region is anticipated to experience the highest growth in terms of CAGR over the forecast period owing to the availability of effective treatment methods, high unmet clinical needs, rising disposable income levels, and increasing awareness about these products.

16 October 2019

READ

“The global Myeloproliferative Disorders Drugs market is anticipated to surpass USD 11 Bn by 2030”, says Visiongain

The emergence of a new therapy for myeloproliferative disorders and the accessibility of new drugs is anticipated to drive the market drugs for myeloproliferative disorders.

16 October 2019

READ

Categories

Category